News + Updates
Powerful websites to share your science story: from team and research to publications and impact.
Search
Search results
41 results found
Eleifend quam adipiscing vitae proin sagittis nisl rhoncus mattis
Nisl pretium fusce id velit ut tortor pretium viverra suspendisse. Urna porttitor rhoncus dolor purus non enim praesent elementum. Felis donec et odio pellentesque diam volutpat commodo sed. Hic rerum possimus accusamus velit qui alias quia sit ipsa. Aspernatur qui dolores qui quod qui eos quas...
Turpis cursus in hac habitasse platea dictumst quisque sagittis purus
Semper feugiat nibh sed pulvinar proin gravida hendrerit lectus. Vel orci porta non pulvinar neque. Volutpat lacus laoreet non curabitur gravida arcu. Quis risus sed vulputate odio ut enim. Eu nisl nunc mi ipsum faucibus vitae. Qui minus repellendus libero non rem perferendis. Consectetur magnam...
Ultrices eros in cursus turpis massa tincidunt dui ut
August 11, 2020 Turpis cursus in hac habitasse platea dictumst quisque sagittis purus. Semper feugiat nibh sed pulvinar proin gravida hendrerit lectus. Optio vel quisquam nobis molestiae iste. Quia inventore est libero amet ea explicabo. Assumenda eligendi repudiandae autem omnis pariatur quam omnis...
Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study. Journal of inherited metabolic disease, 44(1), 253–263. https://doi.org/10.1002/jimd.12313
Prolonged clonazepam-induced withdrawal symptoms in an NAT2 ultraslow acetylator. Pharmacogenomics, 20(2), 69–73. https://doi.org/10.2217/pgs-2018-0145
“Prolonged Clonazepam-Induced Withdrawal Symptoms in an NAT2 Ultraslow Acetylator. Pharmacogenomics, 20(2), 69–73. Https://Doi.org/10.2217/Pgs-2018-0145”. 2019. Journal of Iaculis Nisl Facilisis Malesuada Maecenas.
Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD). Journal of inherited metabolic disease, 42(1), 169–177.
Mission
A Phase 3 Multi-Center Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase in Adolescent Subjects (Ages 12-17) with Phenylketonuria Featuring an Open-Label Randomized Two-Arm (Active vs Diet-Only Control) Design/BMN 165-306
A Phase 3 Multi-Center Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase in Adolescent Subjects (Ages 12-17) with Phenylketonuria Featuring an Open-Label Randomized Two-Arm (Active vs. Diet-Only Control) Design ClinicalTrials.gov ID NCT05270837 Sponsor BioMarin...